Antibe Therapeutics Inc. (ATBPF) 是一家上市公司 属于 医疗保健 板块，经营于 Medical - Devices 行业. 公司总部位于 Toronto, ON, 加拿大. 现任CEO为 Daniel Marcel Legault.
ATBPF 拥有 IPO日期为 2014-10-09, 11 名全职员工, 在 Other OTC, 市值为 $11.43M.
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.
